These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1287 related articles for article (PubMed ID: 19631946)

  • 21. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
    Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study].
    González-Juanatey JR; Cea-Calvo L; Bertomeu V; Aznar J;
    Rev Esp Cardiol; 2007 Feb; 60(2):148-56. PubMed ID: 17338880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
    Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
    Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
    Am Heart J; 2010 May; 159(5):833-40. PubMed ID: 20435193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
    J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standard electrocardiographic criteria for left ventricular hypertrophy in Nigerian hypertensives.
    Dada A; Adebiyi AA; Aje A; Oladapo OO; Falase AO
    Ethn Dis; 2005; 15(4):578-84. PubMed ID: 16259479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    Blood Press; 2014 Apr; 23(2):71-80. PubMed ID: 23721506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
    Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM; Hille DA; Kjeldsen SE; Devereux RB
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy.
    Hsieh BP; Pham MX; Froelicher VF
    Am Heart J; 2005 Jul; 150(1):161-7. PubMed ID: 16084164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Julius S; Snapinn S; Dahlöf B;
    Hypertension; 2004 Jul; 44(1):48-54. PubMed ID: 15173125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM; Boman K; Gohlke-Baerwolf C; Kesäniemi YA; Nienaber C; Ray S; Egstrup K; Rossebø AB; Devereux RB; Køber L; Willenheimer R; Wachtell K
    Circulation; 2012 Jan; 125(2):346-53. PubMed ID: 22147903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
    Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.